Pulse Biosciences Showcases nPulse Cardiac Tech at HRS 2026 with Key Clinical Data
Event summary
- Pulse Biosciences will present late-breaking clinical trial updates on its nPulse Cardiac Catheter at the HRS 2026 Annual Meeting (April 23-26).
- One-year outcomes from a European feasibility study on nanosecond PFA for atrial fibrillation treatment will be highlighted.
- Live case demonstrations and oral abstract presentations are scheduled, featuring key opinion leaders in cardiology.
The big picture
Pulse Biosciences is leveraging the HRS 2026 Annual Meeting to reinforce its position in the pulsed field ablation market, a rapidly evolving segment of cardiac rhythm management. The focus on one-year clinical data underscores the company's push for long-term efficacy validation, which could be pivotal as it seeks to differentiate itself from established players like Medtronic and Boston Scientific.
What we're watching
- Clinical Validation
- Whether the one-year outcomes from the European feasibility study will support broader adoption of nsPFA technology.
- Market Differentiation
- How Pulse Biosciences positions its nPulse Cardiac Catheter against competing ablation technologies in the atrial fibrillation space.
- Regulatory Pathway
- The pace at which Pulse Biosciences advances regulatory approvals for its nsPFA technology based on these clinical results.
Related topics